Long-term persistence of neutralizing memory B cells in SARS-CoV-2
Field | Value | Language |
dc.contributor.author | Bull, Rowena | en_AU |
dc.contributor.author | Abayasingam, Arunasingam | en_AU |
dc.contributor.author | Balachandran, Harikrishnan | en_AU |
dc.contributor.author | Agapiou, David | en_AU |
dc.contributor.author | Rodrigo, Chaturaka | en_AU |
dc.contributor.author | Keoshkerian, Elizabeth | en_AU |
dc.contributor.author | Li, Hui | en_AU |
dc.contributor.author | Brasher, Nicholas | en_AU |
dc.contributor.author | Christ, Daniel | en_AU |
dc.contributor.author | Rouet, Romain | en_AU |
dc.contributor.author | Burnett, Deborah | en_AU |
dc.contributor.author | Grubor-Bauk, Branka | en_AU |
dc.contributor.author | Rawlinson, William | en_AU |
dc.contributor.author | Turville, Stuart | en_AU |
dc.contributor.author | Aggarwal, Anupriya | en_AU |
dc.contributor.author | Brilot, Fabienne | en_AU |
dc.contributor.author | Mina, Michael | en_AU |
dc.contributor.author | Post, Jeffrey | en_AU |
dc.contributor.author | Hudson, Bernard | en_AU |
dc.contributor.author | Gilroy, Nicky | en_AU |
dc.contributor.author | Dwyer, Dominic | en_AU |
dc.contributor.author | Sasson, Sarah | en_AU |
dc.contributor.author | Tea, Fiona | en_AU |
dc.contributor.author | Pilli, Deepti | en_AU |
dc.contributor.author | Tedla, Nicodemus | en_AU |
dc.contributor.author | Lloyd, Andrew | en_AU |
dc.contributor.author | Martinello, Marianne | en_AU |
dc.date.accessioned | 2020-12-21 | |
dc.date.available | 2020-12-21 | |
dc.date.issued | 2020 | en_AU |
dc.identifier.uri | https://hdl.handle.net/2123/24220 | |
dc.description.abstract | Considerable concerns relating to the duration of protective immunity against SARS-CoV-2 have been raised, with evidence of antibody titres declining rapidly after infection and reports of reinfection. Here we monitored antibody responses against SARS-CoV-2 receptor binding domain (RBD) for up to six months after infection. While antibody titres were maintained, half of the cohort's neutralising responses had returned to background. However, encouragingly in a selected subset of 13 participants, 12 had detectable RBD-specific memory B cells and these generally increased out to 6 months. Furthermore, we were able to generate monoclonal antibodies with SARS-CoV-2 neutralising capacity from these memory B cells. Overall our study suggests that the loss of neutralising antibodies in plasma may be countered by the maintenance of neutralising capacity in the memory B cell repertoire. | en_AU |
dc.language.iso | en | en_AU |
dc.subject | COVID-19 | en_AU |
dc.subject | Coronavirus | en_AU |
dc.title | Long-term persistence of neutralizing memory B cells in SARS-CoV-2 | en_AU |
dc.type | Preprint | en_AU |
dc.identifier.doi | 10.21203/rs.3.rs-92527/v1 |
Associated file/s
There are no files associated with this item.
Associated collections